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A B S T R A C T
Bird to human transmission of high pathogenicity avian influenza virus (HPAIV) poses a significant risk of
triggering a flu pandemic in the human population. Therefore, vaccination of susceptible poultry during an
HPAIV outbreak might be the best remedy to prevent such transmissions. To this end, suitable formulations and
an effective mass vaccination method that can be translated to field settings needs to be developed. Our previous
study in chickens has shown that inhalation of a non-adjuvanted dry powder influenza vaccine formulation
during normal breathing results in partial protection against lethal influenza challenge. The aim of the present
study was to improve the effectiveness of pulmonary vaccination by increasing the vaccine dose deposited in the
lungs and by the use of suitable adjuvants. Two adjuvants, namely, Bacterium-like Particles (BLP) and Advax,
were spray freeze dried with influenza vaccine into dry powder formulations. Delivery of dry formulations
directly at the syrinx revealed that BLP and Advax had the potential to boost either systemic or mucosal immune
responses or both. Upon passive inhalation of dry influenza vaccine formulations in an optimized set-up, BLP and
Advax/BLP adjuvanted formulations induced significantly higher systemic immune responses than the non-
adjuvanted formulation. Remarkably, all vaccinated animals not only survived a lethal influenza challenge, but
also did not show any shedding of challenge virus except for two out of six animals in the Advax group. Overall,
our results indicate that passive inhalation is feasible, effective and suitable for mass vaccination of chickens if it
can be adapted to field settings.
1. Introduction
Outbreaks of avian influenza in poultry are the major source of
H5N1 infection in humans [1–3]. These outbreaks, caused by highly
pathogenic strains of avian influenza virus, pose a significant risk of
poultry-human transmission. Currently, the only remedy to control
these outbreaks is to cull the poultry. For safety reasons animals are not
only culled on infected farmyards but also on non-infected neighboring
farmyards [4,5]. The slaughter of millions of poultry not only leads to
severe economic losses but also raises ethical questions and in-
comprehension within the society.
To combat outbreaks of avian influenza virus, it could be useful to
rapidly vaccinate the poultry in areas surrounding the outbreak, in a
ring fencing strategy. However, this would require that very large
numbers of poultry, potentially in the tens or hundreds of millions,
should be able to be immunized within a very short time period. This
would require a vaccine formulation and route of immunization that
are suitable for such mass application. Liquid or powder influenza
vaccine formulations that can be aerosolized and administered via the
respiratory tract could be appropriate formulations for mass vaccina-
tion. Liquid formulations of inactivated influenza virus have been
shown to be inadequate for aerosol vaccination by single administration
[6]. Powder formulations, on the other hand, have shown an advantage
over liquid formulations because of their long-term storage stability
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[7–9]. This long term stability facilitates stockpiling and thus provides
ease of administration during mass vaccination [10]. In a previous
study, we have shown that pulmonary immunization by dispersion of a
dry powder influenza vaccine directly at the syrinx of chickens (active
administration) was able to completely protect these animals against
lethal viral challenge [11]. However, in realistic situations, due to ex-
treme time pressures, active administration of chickens is unsuitable for
mass vaccination. A more realistic approach would be to let chickens
inhale aerosolized dry powder influenza vaccine formulation during
breathing (passive administration). Indeed, passive inhalation of dry
powder influenza vaccine formulation was feasible in chickens, but the
animals were only partially protected indicated by a delay in time to
death and reduced virus shedding [11]. Hence, the efficiency of influ-
enza immunization by passive inhalation must be improved for pul-
monary vaccination to become feasible. Possible approaches could be to
increase the concentration of aerosolized vaccine, to expose the animals
to aerosolized powder for longer periods of time and to include an
adjuvant in the vaccine formulation.
An effective adjuvant should not only be cheap, readily available
and potent, but also safe. An adjuvant that has been generally re-
cognized as safe is BLP. BLP are produced by hot acid treatment (pH 1
for 30min at 99 °C) of Lactococcus lactis, a non-pathogenic, food-grade
Gram-positive bacterium [12,13]. BLP act as Toll-like receptor-2 ligand
and have shown potent immune boosting properties when administered
together with vaccines against influenza, Yersinia pestis, malaria, and
pneumococcal disease [14–17]. Besides Toll-like receptor ligands,
naturally derived polysaccharides, for example Advax™ adjuvant com-
prising an insoluble isoform of inulin, boosts vaccine responses through
mechanism that are still not fully characterized [18]. In (pre) clinical
studies Advax has been shown to enhance immune responses induced
by a wide variety of vaccines including vaccines against Hepatitis B,
SARS coronavirus, listeria and influenza [19–24]. Upon parenteral ad-
ministration, Advax has been shown to have a good safety and toler-
ability record both in animal studies and clinical trials [25–27].
The aim of the current study was to investigate whether passive
administration with dry non-adjuvanted or adjuvanted influenza for-
mulations has the potential to completely protect chickens against le-
thal HPAIV challenge. For this, we initially tested whether (a) BLP or
Advax could be co-formulated with influenza vaccine into dry powder
formulations that are suitable for pulmonary immunization; (b) the
adjuvants have the potential to boost systemic and mucosal immune
responses to influenza; (c) passive administration with either non-ad-
juvanted or adjuvanted influenza formulations would protect chickens
against a lethal HPAIV challenge.
2. Materials and methods
2.1. Virus
For immunization, a reassortant virus, NIBRG-23, prepared by re-
verse genetics from A/turkey/Turkey/1/2005 (H5N1) virus and A/PR/
8/34 (H1N1) virus was used (NIBSC code: 08/156). The virus was
cultured in embryonated chicken eggs by allantoic inoculation of the
seed virus. The virus was purified and inactivated as described pre-
viously to obtain whole inactivated virus vaccine (WIV) [11,28].
For challenge, a highly pathogenic avian influenza virus strain A/
turkey/Turkey/1/2005 (H5N1) (Clade 2.2.1), obtained from the
Animal Health and Veterinary Laboratories Agency, Weybridge, UK was
used.
2.2. Spray freeze drying (SFD)
For active administration, 5.0, 1.0, and 0.2 µg HA of NIBRG-23 WIV
was SFD either as such or admixed with adjuvants (BLP, Mucosis,
Groningen, The Netherlands or Advax, Vaxine, Adelaide, Australia) in
various ratios. For active administration, the dose of BLP and Advax in
1mg of SFD powder was 150 µg and 500 µg respectively. WIV was
mixed with BLP in weight ratios of HA:BLP of 1:30, 1:150 and 1:750.
For WIV-Advax, the weight ratios of HA:Advax were 1:100, 1:500 and
1:2500. Likewise, for passive administration, 5 µg HA of NIBRG-23 was
SFD either as such or mixed with 300 µg of BLP or 500 µg of Advax (this
dose corresponds to the amount of HA and adjuvants in 1mg of SFD
powder). Both non-adjuvanted and adjuvanted formulations were SFD
using inulin (4 kDa, Sensus, Roosendaal, The Netherlands) as the sta-
bilizer. Inulin used for stabilization of influenza vaccine is amorphous
and water soluble with potentially no adjuvant effect whereas Advax
(delta inulin) is crystalline and insoluble in water with potent adjuvant
activity. In brief, a 5% (w/v) solution of WIV and inulin with or without
adjuvants was pumped at a flowrate of 5ml/min through a two-fluid
nozzle of a Büchi 190Mini SprayDryer (Büchi, Flawil, Switzerland). An
atomizing airflow of 600 L/h was used to spray vaccine preparations in
a vessel of liquid nitrogen. Then, the frozen vaccine preparations were
placed in a Christ Epsilon 2–4 freeze dryer precooled to a shelf tem-
perature of −35 °C and at a pressure of 0.220mbar. The shelf tem-
perature was slowly increased from −35 °C to 4 °C within the time
period of 32 h. During the next 12 h, the temperature was further in-
creased to 20 °C and pressure was lowered to 0.05mbar. The dry vac-
cine powder was collected in a climate box with a relative humidity
of< 1% and stored under airtight conditions.
2.3. Physical and biological characterization of influenza vaccine and
adjuvants before and after SFD
2.3.1. Transmission electron microscopy
A Philips CM120 transmission electron microscope was used to
make transmission electron microscopy images. SFD powders con-
taining WIV (5 µg HA formulation) with or without adjuvants i.e. BLP
(300 µg in 1mg of SFD powder), Advax (500 µg in 1mg of SFD powder)
were reconstituted in sterile filtered water. Liquid and reconstituted
SFD formulations were placed on a plain carbon grid, rinsed with water
and then samples were stained twice with 5 µL of 2 wt-% uranyl acetate.
A Gatan type UltraScan 4000SP CCD Camera at a magnification was
used to take images.
2.3.2. Hemagglutination assay
The receptor binding activity of WIV after SFD with or without
adjuvants was assessed by hemagglutination assay. SFD powders were
reconstituted in phosphate buffer saline (PBS) to a concentration of
20 µg/ml of HA. Then, 50 µL of the preparation was added to 96-well V
bottom plates containing 50 µL of PBS. The entire mixture was two-fold
serially diluted, then 50 µL of 1.5% guinea pig red blood cell suspension
was added to each well. The plate was allowed to stand undisturbed for
two hours at room temperature. Hemagglutination titers read after two
hours were expressed as log2 of the highest dilution where red blood
cell agglutination could be seen.
2.3.3. Quanti-blue assay
The capacity of BLP to activate NF-κB via Toll-like receptor-2 was
evaluated using RAW-Blue™ cells (InvivoGen, Toulouse, France). RAW-
Blue™ cells have a number of pattern recognition receptors which when
bound to agonists leads to activation of NF-κB and thus the production
of secreted alkaline phosphatase. A schematic illustration is shown in
Fig. S1. Cells were maintained in DMEM with high glucose (Gibco Life
Technologies BV, Bleiswijk, The Netherlands), 10% FBS (Lonza, Basel,
Switzerland), 100 µg/ml Normocin™ (InvivoGen, Toulouse, France),
2 mM L-glutamine and passaged when 70–80% confluency was
reached. Approximately 5×104 cells were added to 96-well flat
bottom plates and were stimulated with 1.7 µg untreated BLP or with
liquid and reconstituted SFD powder formulations with (5 µg
HA+300 µg BLP formulation) or without 1.7 µg BLP. The incubation
was maintained for 18 h at 37 °C with 5% CO2. To measure alkaline
phosphatase levels, 150 µL QUANTI-Blue™ (InvivoGen, Toulouse,
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France) was added to the cell supernatant and after 1 h, absorbance was
measured at 630 nm using a spectrophotometer.
2.3.4. Scanning electron microscopy
SFD-WIV preparations were imaged using a JEOL JSM 6301-F mi-
croscope (JEOL. Ltd., Tokyo, Japan). Powders were placed on double-
sided sticky carbon tape on a metal disc and the particles were coated
with approximately 10 nm of gold using a Balzer’s 120B sputtering
device (Balzer UNION, Liechtenstein). A magnification of 500× and
5000× was used to capture the images.
2.3.5. Particle size analysis
Geometrical particle size distribution of the powders were measured
using a HELOS compact model KA laser diffraction apparatus
(Sympatec GmbH, Clausthal-Zellerfeld, Germany). To disperse the
powders, the highly efficient RODOS dispersing system (Sympatec
GmbH, Clausthal-Zellerfeld, Germany) was used at a pressure of 1 bar.
Aerodynamic particle size distribution was calculated using the equa-
tion described by Bhide et al. [29].
2.4. Vaccination-challenge
2.4.1. Active administration and sample collection
Sixty 3-week old specific-pathogen free chickens (White Leghorn)
were randomly divided into 10 groups of 6 animals. Animals were
immunized twice i.e. on day 0 and day 14. SFD-WIV formulations (ei-
ther non-adjuvanted or adjuvanted with BLP or Advax) were adminis-
tered to the animals using a DP-4-C Dry Powder Insufflator (Penn-
Century Inc., Philadelphia, USA). A custom length delivery tube de-
signed to deliver the powder directly at the syrinx was used. Three puffs
of 1ml air were used to aerosolize 1mg of powder filled in the insuf-
flator. The animals were sacrificed on day 28.
Blood samples were taken on day 0 (before the 1st immunization),
day 14 (two weeks after the 1st immunization) and day 28 (two weeks
after the 2nd immunization). On the day of sacrifice (day 28), lung
lavages were collected by flushing lungs with 20ml of PBS as described
by Holt et al. [30]. The obtained sera and lung lavages were stored at
−20 °C until further use.
An overview of the immunization scheme and groups is shown in
Fig. 1A and B.
2.4.2. Passive administration and challenge
For passive administration of non-adjuvanted and adjuvanted WIV
formulations, 24 3-week old specific-pathogen free chickens were ran-
domly divided into 4 groups of 6 chickens. One animal died of unknown
causes before the start of the experiment. Each group was placed in a
customized box with a volume of 0.035m3. A 5ml Eppendorf tube filled
with 100mg of SFD powder containing 0.5 mg HA of NIBRG-23 WIV
with or without adjuvants was punctured at the bottom with a 29G
hypodermic needle. The lid of the Eppendorf tube was fitted to a
pressurized air container while the bottom conical part of the tube was
inserted airtight in a hole drilled in the customized box for the dis-
persion of powders. The SFD powders were aerosolized in the box by
using several pulses of pressurized air, resulting in a theoretical con-
centration of 14mg HA/m3 (HA dose for dispersion: 0.5 mg, inhalation
box volume: 0.035m3). For the first vaccination, the animals were ex-
posed to the aerosolized vaccine for 20min and after every 2min short
pulses of medicinal oxygen (20 s; flow rate 0.5 L/min) were supplied
through another hole in the box. For the second vaccination (2weeks
later i.e. on day 14) the exposure time was 12min with short pulses of
oxygen (13 s; flow rate 0.5 L/min) every minute. Based on the re-
spiration rate for chickens of 44 L/h/kg body weight [31,32] these
exposure times would result in a maximum theoretical dose of 50 µg HA
per animal per application.
The EID50 (50% embryo-infectious dose) titre of the challenge strain
stock of A/turkey/Turkey/1/2005 (8.1 log10 EID50/ml) was used to
calculate the dilution for the challenge virus. The 50% chicken lethal
dose of A/turkey/Turkey/1/2005 virus is 2.5 log10 EID50 [33]. On day
Fig. 1. An overview of the immunization scheme and immunized groups. Active administration: immunization scheme (A), immunized groups (B). Passive
administration: immunization scheme (C), immunized groups (D). * Represents group which received only inulin (placebo), # represents 1st im-
munization with Advax and 2nd immunization with BLP. In the passive inhalation set up, the vaccine and adjuvant dose states the theoretical/calculated
dose.
J. Tomar et al. European Journal of Pharmaceutics and Biopharmaceutics 133 (2018) 85–95
87
28, animals were challenged with a lethal dose of 5.0 log10 EID50 of this
virus by the combined intranasal/intratracheal route (liquid suspen-
sion; 0.1 ml each). For back titration, we determined TCID50 (50%
tissue culture infectious dose). The titre (10log TCID50/ml) after back-
titration of the challenge virus that we received from the stables after
the challenge inoculation was 4.2 whereas the titre of the original stock
was 6.8. Thus, a titre of 8.1 EID50/ml corresponds to 6.8 TCID50/ml.
The titre of 4.2 TCID50/ml for the back-titration should therefore cor-
respond to at least 5.0 EID50/ml. Since the 50% chicken lethal dose of
the challenge virus is 2.5 log10 EID50, a dose of 4.3 10logEID50 (0.2 ml
of 5.0 EID50/ml) is more than sufficient (> 60× CLD50) to kill non-
vaccinated animals. In previous studies with the same virus batch and
dilution, we found that this dose killed all non-vaccinated control group
animals within 2–3 days after the challenge [11,34].
In this study, after challenge, animals were observed for clinical
signs and on 1, 3, 5, 7 and 10 days post challenge choanal and cloacal
swabs were collected for virus quantification. On day 42, the animals
were sacrificed. An overview of the immunization-challenge scheme
along with groups is shown in Fig. 1C and D. Passive inhalation of dry
formulations could be seen in video file (supplementary data).
2.4.3. Virus quantification by RT-PCR
Virus titers in choanal and cloacal swabs were determined as per the
method described by van der Goot et al. [35]. Challenge virus was ten-
fold serially diluted, followed by RNA extraction, and a standard curve
consisting of the RNA from these serial dilutions was prepared. As per
the standard curve, PCR data was converted into equivalent virus titers
(eqTCID50/ml).
2.4.4. ELISA
Serum samples and lung washes were used for the determination of
IgY and IgA antibody titers. For the determination of IgY titers, ELISA
was performed as previously described [36], except that the secondary
antibody consisted of goat anti chicken IgY-HRP (Southern Biotech,
Birmingham, USA). IgY titers were determined as log10 of the reciprocal
of the sample dilution corresponding to an absorbance of 0.2 at the
wavelength of 492 nm. IgA titers were determined in lung washes using
the commercially available chicken IgA ELISA kit as per manufacturer’s
instructions (Abcam, Cambridge, UK).
2.4.5. Hemagglutination inhibition (HI) assay
HI assay was performed as described previously [11]. Briefly, 8
hemagglutination units of inactivated virus A/turkey/Turkey/1/05
(H5N1) were added to two-fold diluted sera samples. HI titers were
recorded as highest serum dilution capable of preventing hemaggluti-
nation. HI titers are presented on log2 scale.
2.4.6. Micro-neutralization assay
Micro-neutralization titers were determined as previously described
[37]. Briefly, two-fold serial dilutions of serum samples were prepared
and 50 TCID50 of NIBRG-23 virus was added to each well of 96 well
plate. After 2 h of incubation at 37 °C, the mixture of serum and virus
was transferred to MDCK cells (ATCC, Germany) cultured in 96-well flat
bottom plate. After 1 h of incubation at 37 °C, the supernatant was
discarded and replaced with Episerf-medium (100 U/ml penicillin,
100mg/ml streptomycin, 1M HEPES and 7.55% sodium bicarbonate,
all Life Technologies™ BV, Bleiswijk, The Netherlands) supplemented
with 5 µg/ml of TPCK trypsine (Sigma-Adrich, The Netherlands). After
72 h of incubation, the supernatant was transferred to 96 V bottom
plate. Micro-neutralization titers were calculated by finding the highest
serum dilution capable of preventing hemagglutination. Micro-neu-
tralization titers are presented on log10 scale.
2.4.7. Statistics
Mann-Whitney one tailed test was used to compare whether the
differences between non-adjuvanted and adjuvanted influenza vaccine
formulations were significant. Levels of significance are denoted as
*p≤ 0.05, **p≤ 0.01, ***p≤ 0.001 respectively.
3. Results
3.1. Physical and biological characterization of influenza vaccine and
adjuvants after SFD
In order to investigate the potential of BLP and Advax as mucosal
adjuvants in chickens, it was essential to investigate whether the phy-
sical and biological properties of WIV and adjuvants remained un-
altered during SFD.
To evaluate whether admixing adjuvants with WIV and SFD had an
influence on the physical appearance of WIV, BLP or Advax particles,
transmission electron microscopy analysis was performed for these
samples before and after SFD. The powder samples were reconstituted
prior to use. Transmission electron microscopy pictures showed that
WIV, BLP and Advax particles had comparable morphological appear-
ance before and after SFD (Fig. 2A–C). Thus, neither the stress en-
countered during SFD nor admixing adjuvants with WIV had any ad-
verse effect on their physical appearance.
The biological activity of WIV needs to be preserved both after the
addition of adjuvants and after SFD. In order to investigate whether the
receptor binding activity of HA was preserved, hemagglutination assay
was performed. No differences in hemagglutination titers could be de-
tected either by the addition of adjuvants or by SFD, thus indicating no
detrimental effects of adjuvants or SFD on the biological activity of HA
(Fig. 2D).
Furthermore, the effect of SFD on the biological activity of BLP was
evaluated. For this purpose, reconstituted BLP-adjuvanted SFD WIV
formulations were compared to unprocessed dispersion of liquid WIV
and BLP for their capacity to activate NFκB using RAW-BLUE™ cells.
NIBRG-23 derived WIV alone was found to be a poor activator of NFκB.
Reconstituted BLP-adjuvanted WIV formulations activated NFκB to a
similar extent as native liquid WIV-BLP dispersion. Thus, stress en-
countered during SFD had no effect on the biological activity of BLP to
activate Toll-like receptor 2 (Fig. 2E).
3.2. Physical characterization of powders
To assess whether the incorporation of BLP or Advax in the SFD
formulation had an effect on the physical characteristics of powder
particles, scanning electron microscopy was used to analyze physical
appearance of SFD formulations. Spherical shaped intact particles with
an interconnected porous structure could be seen for both non-ad-
juvanted and adjuvanted WIV formulations. No major differences could
be observed in the morphology of SFD particles by varying the dose of
HA and by the addition of adjuvants. Representative pictures of non-
adjuvanted, BLP and Advax adjuvanted WIV formulation at an HA dose
of 0.2 µg per mg of powder are shown in Fig. 3A–C. Further, upon
determination of geometric particle size, average particle size (X50) was
found to be between 8 and 12 µm both for non-adjuvanted and ad-
juvanted WIV formulations (Fig. 3D). However, for inhalation, an
aerodynamic particle size of 1–5 µm is considered to be most suitable
[29]. The average aerodynamic particle size of non-adjuvanted as well
as adjuvanted WIV formulations was calculated according to the for-
mula described by Bhide et al. [29]. The average aerodynamic particle
size was found to be ≤3.7 µm and the majority of the particles (X90)
had size ≤5 µm (Fig. 3E). Particles with a size range between 1 and
3.7 µm are considered to be suitable for deposition in the entire re-
spiratory tract of chickens [38–40].
Overall, our results indicated that SFD can produce BLP and Advax-
adjuvanted WIV particles with physical and biological characteristics
that make them suitable for pulmonary vaccination.
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3.3. Immune responses induced by active administration
For active administration, the tip of the insufflator was placed di-
rectly at the syrinx of chickens and three puffs of 1ml air were used to
disperse the powders. We next evaluated the systemic and mucosal
immune responses induced in chickens after active administration.
Serum IgY and HI titers were measured both at day 14 and day 28
whereas serum MN, lung IgY and IgA titers were measured only at day
28. On day 14, non-adjuvanted as well as adjuvanted WIV formulations
had induced considerable serum IgY titers. Advax-adjuvanted WIV
formulations induced significantly higher serum IgY titers than the
corresponding non-adjuvanted WIV formulations (Fig. 4A). However,
no major differences were found among non-adjuvanted and BLP-ad-
juvanted WIV formulations, except between corresponding 0.2 µg HA
formulations (Fig. 4A). Although, this difference was statistically sig-
nificant, it was not major. However, on day 28, significantly higher
titers were induced by BLP-adjuvanted WIV formulations than by the
non-adjuvanted WIV formulation at an HA dose of 0.2 and 5 µg; the
difference between non-adjuvanted and BLP-adjuvanted formulations
was not significant at HA dose of 1 µg (Fig. 4B). For Advax-adjuvanted
WIV formulation, significantly higher titers than corresponding non-
adjuvanted WIV formulation were only induced by the 5 µg HA for-
mulation (Fig. 4B).
Systemic immune responses were further assessed by determining
serum HI titers. It was found that after the first vaccination i.e. at day
14, none of the vaccinated chickens had detectable HI titers (Fig. 4C).
However, after the second vaccination, BLP-adjuvanted WIV formula-
tions, at a dose of 5 and 0.2 µg HA, induced a trend towards higher HI
titers (mean HI titers of 5.2 log2 and 2.7 log2 respectively) than cor-
responding non-adjuvanted WIV formulations (mean HI titers of 4.2
log2 and 0 respectively) (Fig. 4C). Though at an HA dose of 5 µg, the
difference was not statistically significant, but at an HA dose of 0.2 µg,
significantly higher titers could be seen for BLP-adjuvanted WIV for-
mulation than corresponding non-adjuvanted formulation. Also, com-
pared to non-adjuvanted WIV formulation (0), a small but non-sig-
nificant increase in HI titers was seen for the Advax-adjuvanted WIV
formulation at the lowest HA dose of 0.2 µg (0.58 log2) (Fig. 4C). At day
28, micro-neutralization titers were found to be in line with HI titers. In
comparison to non-adjuvanted WIV formulation, Advax and BLP-ad-
juvanted WIV formulations at a dose of 0.2 µg HA induced an increase
in the micro-neutralization titers of about five and eight fold, respec-
tively (Fig. 4D). No major differences were seen at 5 µg and 0.2 µg HA
dose.
Mucosal immune responses were assessed by determining IgA and
IgY titers in the lung lavages obtained two weeks after the second im-
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Fig. 2. Physical and biological characterization of influenza vaccine and adjuvants. (A–C) Transmission electron microscopy pictures of (A) WIV (left-
upper panel), WIV-BLP showing WIV (right-upper panel), SFD WIV (left-lower panel), SFD WIV-BLP showing WIV (right-lower panel), (B) WIV-BLP
showing BLP (left), SFD WIV-BLP showing BLP (right), (C) WIV-Advax showing Advax (left), SFD WIV-Advax showing Advax (right); (D) Hemagglutination
titers of non-adjuvanted and adjuvanted WIV formulations; (E) NFκB activity of non-adjuvanted and BLP adjuvanted WIV formulations before and after
SFD. Data of hemagglutination assay titers and NFκB are presented as average± standard error of the mean (n = 6).
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titers after the second immunization. BLP-adjuvanted WIV formulations
induced significantly higher lung IgY titers than respective non-ad-
juvanted WIV formulations at a dose of 0.2 and 5 µg HA (Fig. 4E). In
addition, Advax-adjuvanted WIV formulations induced higher lung IgY
titers than non-adjuvanted WIV formulation at an HA dose of 0.2 µg,
though the difference was not significant (Fig. 4E). Though non-ad-
juvanted WIV formulations were found to induce considerable lung IgA
titers, the inclusion of BLP and Advax further boosted the immune re-
sponses (Fig. 4F). It was found that at a dose of 5 µg HA, BLP-ad-
juvanted WIV formulation boosted lung IgA titers (3.6 log10) by ap-
proximately four fold in comparison to corresponding non-adjuvanted
WIV formulation (3.2 log10) (Fig. 4F). For Advax-adjuvanted WIV for-
mulations, at a dose of 0.2 and 1 µg HA, lung IgA titers were augmented
by three to five fold as compared to corresponding non-adjuvanted WIV
formulations (Fig. 4F).
3.4. Immune responses induced by passive administration
Passive administration might be a suitable method for mass vacci-
nation of chickens. For passive administration, chickens placed in a
custom made box were allowed to inhale aerosolized vaccine powders
during breathing using two applications 2 weeks apart. We next
evaluated the systemic immune responses induced in chickens after
passive administration of these aerosolized powders. Serum IgY titers
were determined at day 14 and day 28 whereas micro-neutralization
titers were determined at day 28. Adjuvanting with BLP or Advax re-
sulted in significantly higher serum IgY titers at day 14; an increase of
about three to five fold could be seen by the co-administration of BLP or
Advax with WIV (Fig. 5A). However, after the second vaccination, only
BLP and Advax/BLP adjuvanted WIV formulations had significantly
higher serum IgY titers (4.8–5.1 log10) than non-adjuvanted WIV for-
mulation (4.5 log10) (Fig. 5B). The augmentation in serum IgY titers
was about six-fold for BLP-adjuvanted WIV and three fold for Advax/
BLP-adjuvanted WIV (Fig. 5B).
Trends in HI titers were in agreement with serum IgY titers both
after the first and second immunization. After the first immunization,
all three formulations i.e. BLP, Advax and Advax/BLP adjuvanted WIV
formulations showed significantly higher HI titers (mean HI titers be-
tween 3.0 and 3.5 log2) than non-adjuvanted WIV formulation (mean
HI titer 1.9 log2) (Fig. 5C). Notably, after the second immunization, BLP
adjuvanted and Advax/BLP-adjuvanted WIV formulations induced sig-
nificantly higher HI titers (mean HI titers between 7.8 and 8.4 log2)
than non-adjuvanted WIV or Advax adjuvanted WIV (mean HI titers of
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Fig. 3. Physical characterization of SFD vaccine powders. Scanning electron microscope pictures of non-adjuvanted and adjuvanted WIV formulations
(0.2 µg HA dose) at a magnification of 500× (left) and 5000× (right). (A) WIV, (B) WIV-BLP, (C) WIV-Advax. (D) X10, X50 and X90 undersize values of the
geometric size distribution of non-adjuvanted and adjuvanted WIV formulations, (E) Aerodynamic particle size. Data of geometric and aerodynamic
particle size are presented as average± standard error of the mean (n = 4).
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second immunization were also in line with serum IgY and HI titers.
BLP and Advax/BLP adjuvanted WIV formulations induced six-fold
higher micro-neutralization titers (3.6 log10) than non-adjuvanted WIV
formulation (2.9 log10) (Fig. 5D).
3.5. Shedding of challenge virus: passive administration
To assess whether passive administration of non-adjuvanted or ad-
juvanted influenza vaccine formulations, has the potential to reduce/
diminish the shedding of challenge virus after lethal challenge, virus
shedding was determined in choanal and cloacal swabs. In our previous
study, we found out that non-vaccinated animals shed virus until they
succumbed to infection (3 days post challenge) [11]. In this study, a
similar dose of A/turkey/Turkey/1/2005 virus was used to challenge
chickens by the combined intranasal/intratracheal route. No virus was
found either in choanal or cloacal swabs of animals immunized with
non-adjuvanted or BLP adjuvanted or Advax/BLP adjuvanted WIV
formulations (Table 1). Only two animals immunized with Advax-ad-
juvanted WIV formulation showed virus in their choanal swabs
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Fig. 4. Immune responses induced by active administration of chickens with various influenza vaccine formulations. Chickens were immunized twice
with non-adjuvanted or adjuvanted WIV formulations delivered directly at the syrinx. Two weeks after the second immunization, chickens were sa-
crificed and immune responses were evaluated. Serum IgY titers on day 14 (A) and day 28 (B); (C) HI titers at day 14 and day 28; (D) Micro-neutralization
titers at day 28; (E) Lung IgY titers; (F) Lung IgA titers. Data are presented as average± standard error of the mean (n = 6). Levels of significance are
presented as *p ≤ 0.05 and **p ≤ 0.01; * in HI titers represent significance compared to corresponding non-adjuvanted WIV formulation.
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and the other animal had virus cleared by day 7. None of these animals
had virus shedding in their cloacal swabs except for one animal which
had a very low level of virus shedding on 3 days post challenge.
4. Discussion
In this study, we demonstrated that BLP and Advax can be co-for-
mulated with influenza vaccine into a dry formulation that is suitable
for pulmonary immunization of chickens. Upon active administration of
chickens, the adjuvants BLP and Advax were shown to augment sys-
temic and mucosal immune responses. Remarkably, in an optimized set-
up, passive administration of chickens either with non-adjuvanted or
BLP or Advax adjuvanted WIV formulations induced robust immune
responses that were sufficiently high to protect chickens against lethal
viral challenge. Furthermore, BLP and Advax/BLP adjuvantation sig-
nificantly raised the level of antigen-specific serum antibodies. In real
life situations, where passive inhalation would be performed in large
rooms, a portion of the aerosolized vaccine formulation would also end
up in food and water. However, previous studies have shown that HA of
the influenza vaccine undergoes conformational changes at acidic pH
and is thus susceptible to proteolytic cleavage in the acidic environment
[41,42]. Consequently, little-no neutralizing antibodies are induced by
acidic pH treated influenza vaccine [41,42]. Therefore, it is speculated
that the acidic environment in the stomach of chickens would not really
add up to the lung induced mucosal immunity.
The crystalline nature of Advax and peptidoglycans on the surface of
BLPs might have detrimental effects on influenza vaccine during the
production of adjuvanted dry powder formulations. However, the in-
clusion of BLP or Advax together with WIV in a formulation led to the
formation of dry powder particles of comparable physical and biolo-
gical characteristics as those of non-adjuvanted WIV formulation.
Moreover, the physical properties of adjuvants i.e. their size and shape
were found to be unaltered after SFD. Also, the biological activity of
BLP was found to be well preserved during SFD.
Previous studies have shown that administration of BLP or Advax
adjuvanted influenza vaccine formulations via the respiratory tract re-
sults in substantial augmentation of systemic and mucosal immune
responses in mice [16,43–46]. In this study we showed that after active
administration, systemic immune responses (serum IgY titers) after one
immunization were predominantly enhanced by Advax whereas after
two immunizations they (serum IgY, HI titers, micro-neutralization ti-
ters) were mainly enhanced by BLP. After two immunizations, both
non-adjuvanted and adjuvanted WIV formulations, at an HA dose of
5 µg, induced average HI titers above 3 log2 which was previously
found to be required for protection against lethal dose of influenza virus
[11]. With respect to mucosal immune responses, lung IgY titers were
mainly enhanced by BLP whereas lung IgA titers were augmented by
both BLP and Advax. Though both BLP and Advax were found to en-
hance either systemic or mucosal immune responses or both, the ob-
served discrepancies might be due to the dose of BLP (150 µg) and
Advax (500 µg) used in this study. Although doses of 150 µg of BLP and

















































































































































Fig. 5. Immune responses induced by passive administration of chickens with various influenza vaccine formulations. Chickens were immunized twice,
by aerosolizing non-adjuvanted or adjuvanted WIV formulations in a custom made box. Two weeks after the second immunization, sera were collected
and immune responses were evaluated. Serum IgY titers at day 14 (A) and day 28 (B), (C) HI titers at day 14 and day 28; (D) Micro-neutralization titers at
day 28. Data are presented as average± standard error of the mean (n = 6). Levels of significance are presented as *p ≤ 0.05 and **p ≤ 0.01. * or #p...and
** or ##p<0.01. Significance is compared to non-adjuvanted WIV formulation.
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systemic and mucosal immune responses in mice, however, these doses
might be too low for chickens with a 10x higher body weight. This
might have resulted in the adjuvant dose to be a limiting factor in the
active administration study.
The active administration study revealed a slight but significantly
higher effect of both BLP and Advax adjuvants, in comparison to non-
adjuvanted WIV formulations. Hence, for the passive administration
study, the relative dose of BLP was increased to double, i.e 300 µg/mg
of SFD powder while keeping the dose of Advax similar. Since Advax
particles consisted of 50 wt% of the SFD powder formulation, enhan-
cing the dose of Advax further would most likely have compromised the
integrity of the powder particles. Moreover, a pattern of Advax being
effective after one and BLP after two immunizations could also be de-
termined in the active administration study. Therefore, one of the
groups of passively administered animals inhaled Advax-adjuvanted
WIV for the first immunization and BLP-adjuvanted WIV for the second
immunization.
In our previous study, passive inhalation led to in-efficient delivery
of influenza vaccine powders to the lungs of chickens and thus provided
only partial protection [11]. Hence, for this study, we aimed for com-
plete protection against lethal influenza viral challenge. This was
achieved by enhancing vaccine powder delivery to the lungs: by in-
creasing the vaccine concentration (by reducing the size of inhalation
box), by increasing the exposure time, and by the use of adjuvants.
Compared to our previous study, optimization of the vaccine con-
centration and exposure time resulted in an increment of ∼7 fold in the
theoretical vaccine dose (this study 2×50 µg HA/animal; previous
study 3×5 µg HA/animal) [11]. Using this optimized set-up, passive
inhalation of both non-adjuvanted and adjuvanted WIV formulations
not only protected chickens against clinical signs after HPAIV chal-
lenge, but also almost completely prevented challenge virus shedding.
These results are a significant improvement over our previous study in
which chickens showed partial protection and challenge virus shedding
even after three immunizations. Though the immunological mechanism
that governed complete protection in chickens by passive administra-
tion of non-adjuvanted and adjuvanted WIV formulations still needs to
be investigated, the shedding data indicate that mucosal immune re-
sponses were high enough to prevent production of substantial amounts
of virus. In addition to mucosal immune responses, an important class
of immune responses are those elicited systemically. At both time
points, BLP and Advax/BLP adjuvanted WIV formulations, were found
to induce higher systemic immune responses than non-adjuvanted or
Advax-adjuvanted WIV preparation. In addition, we found out that,
either of the two adjuvants i.e. Advax or BLP would be appropriate for
first immunization, however, for second immunization, BLP was vital.
Although these adjuvanted WIV formulations elicited significantly
higher immune responses than non-adjuvanted WIV formulation, the
fact that even the non-adjuvanted WIV formulations provided complete
protection, suggests that the use of an adjuvant was not critical for
protection via passive inhalation, but it might add to dose-sparing of
influenza vaccines for future passive inhalation studies.
5. Conclusion
In conclusion, our results show that, vaccination by passive in-
halation of dry influenza vaccine powders is suitable to induce pro-
tective immunity in chickens against highly pathogenic avian influenza
virus. It not only has the potential to completely protect chickens from
morbidity and mortality, and to prevent the virus from spreading, but
also seems to be a feasible option for mass vaccination of chickens. The
challenge now remains to translate passive inhalation vaccination from
the box to real-world field settings.
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Table 1
Virus shedding after challenge.
Virus shedding (eq. TCID50/ml)
Group No. Vaccine Animal No. Choana swabs Cloaca swabs
Day 1 Day 3 Day 5 Day 7 Day 10 Day 1 Day 3 Day 5 Day 7 Day 10
1 WIV 1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
6 NA NA NA NA NA NA NA NA NA NA
2 +BLP 1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
3 +Advax 1 2.0 1.5 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0
2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0
3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
6 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
4 +Advax/BLP 1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
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